Market overview
The global high-end cellomics market is worth USD 610 mn in 2026 and is forecast to reach USD 1.2 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Confocal high-content systems is the largest by system segment.
| Scope | High-content cell imaging and analysis systems (cellomics): automated microscopes with image analysis software used for drug screening and cell biology. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 570 mn |
| Value 2026 | USD 610 mn |
| Value 2036 | USD 1.2 bn |
| CAGR 2026-2036 | 7.0% |
| Volume 2026 | 2,129 units |
| Volume 2036 | 3,985 units |
| Average price 2026 | USD 286,400 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
High-end Cellomics market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 610 mn |
| 2027 | USD 653 mn |
| 2028 | USD 698 mn |
| 2029 | USD 747 mn |
| 2030 | USD 799 mn |
| 2031 | USD 855 mn |
| 2032 | USD 915 mn |
| 2033 | USD 979 mn |
| 2034 | USD 1.0 bn |
| 2035 | USD 1.1 bn |
| 2036 | USD 1.2 bn |
High-end Cellomics market segmentation
By system
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Confocal high-content systems | 42.0% | 43.5% | USD 256 mn | 7.4% |
| Widefield high-content systems | 34.0% | 27.9% | USD 207 mn | 4.9% |
| Live-cell and 3D organoid imagers | 24.0% | 28.6% | USD 146 mn | 8.9% |
By end use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharma and biotech drug discovery | 56.0% | 56.1% | USD 342 mn | 7.0% |
| Academic research | 28.0% | 25.5% | USD 171 mn | 6.0% |
| Contract research organisations | 16.0% | 18.4% | USD 98 mn | 8.5% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Phenotypic drug screening | 34.0% | 32.0% | USD 207 mn | 6.3% |
| Toxicology | 20.0% | 19.0% | USD 122 mn | 6.5% |
| Target identification and validation | 22.0% | 22.0% | USD 134 mn | 7.0% |
| Cell biology research | 24.0% | 27.0% | USD 146 mn | 8.3% |
By offering
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Imaging instruments | 50.0% | 42.0% | USD 305 mn | 5.2% |
| Consumables | 28.0% | 30.0% | USD 171 mn | 7.7% |
| Analysis software | 22.0% | 28.0% | USD 134 mn | 9.6% |
By throughput
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Medium | 38.0% | 34.0% | USD 232 mn | 5.8% |
| High | 40.0% | 42.0% | USD 244 mn | 7.5% |
| Ultra-high | 22.0% | 24.0% | USD 134 mn | 7.9% |
Top 25 countries for high-end cellomics by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 90.5% of 2026 revenue and the 25 countries below together hold 97.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 232 mn | 38.0% | USD 425 mn | 6.2% |
| 2 | China | USD 79 mn | 13.0% | USD 200 mn | 9.7% |
| 3 | Germany | USD 49 mn | 8.0% | USD 90 mn | 6.3% |
| 4 | Japan | USD 43 mn | 7.0% | USD 74 mn | 5.7% |
| 5 | United Kingdom | USD 37 mn | 6.0% | USD 67 mn | 6.3% |
| 6 | France | USD 27 mn | 4.5% | USD 50 mn | 6.3% |
| 7 | Switzerland | USD 24 mn | 4.0% | USD 47 mn | 6.7% |
| 8 | South Korea | USD 24 mn | 4.0% | USD 54 mn | 8.3% |
| 9 | India | USD 18 mn | 3.0% | USD 47 mn | 9.8% |
| 10 | Canada | USD 18 mn | 3.0% | USD 34 mn | 6.3% |
| 11 | Netherlands | USD 4.9 mn | 0.8% | USD 9.2 mn | 6.6% |
| 12 | Australia | USD 4.3 mn | 0.7% | USD 8.2 mn | 6.7% |
| 13 | Singapore | USD 3.7 mn | 0.6% | USD 8.6 mn | 9.0% |
| 14 | Italy | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 15 | Spain | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 16 | Belgium | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 17 | Denmark | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 18 | Sweden | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 19 | Taiwan | USD 3.0 mn | 0.5% | USD 5.8 mn | 6.6% |
| 20 | Israel | USD 2.4 mn | 0.4% | USD 4.7 mn | 6.7% |
| 21 | Ireland | USD 2.4 mn | 0.4% | USD 4.7 mn | 6.7% |
| 22 | Brazil | USD 1.8 mn | 0.3% | USD 4.3 mn | 9.0% |
| 23 | Austria | USD 1.8 mn | 0.3% | USD 3.5 mn | 6.6% |
| 24 | Finland | USD 1.8 mn | 0.3% | USD 3.5 mn | 6.6% |
| 25 | Norway | USD 1.8 mn | 0.3% | USD 3.5 mn | 6.6% |
| Rest of world | USD 15 mn | 2.4% | USD 27 mn | 6.3% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Revvity
- Molecular Devices
- Agilent Technologies
- Carl Zeiss
- Leica Microsystems
Group 2: Regional and specialist players
- Yokogawa Electric
- Olympus
- Nikon
- Cytiva
- Bruker
- Logos Biosystems
- Nanolive
- Hamamatsu Photonics
Group 3: Emerging and niche players
- Cytena
- Sartorius
- Etaluma
- Curiosis
- Oxford Nanoimaging
- Axion BioSystems
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the high-end cellomics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.
The market is divided by system, by end use, by application, by offering, by throughput. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the high-end cellomics market?
The global high-end cellomics market is estimated at USD 570 mn in 2025 and USD 610 mn in 2026.
How fast will the high-end cellomics market grow?
It is forecast to reach USD 1.2 bn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 590 mn.
Which country is the largest market for high-end cellomics?
United States is the largest market by revenue at USD 232 mn in 2026, 38.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 9.8% a year from 2026 to 2036.
Which high-end cellomics segment is largest?
In the by system split, Confocal high-content systems is the largest segment with 42.0% of 2026 revenue.
Who are the leading high-end cellomics companies?
Global leaders include Thermo Fisher Scientific, Revvity, Molecular Devices, Agilent Technologies.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Hospital-at-Home Monitoring PlatformsUSD 608 mn · 15.0% CAGR
- Hospital-at-Home Vital Signs Monitoring PlatformsUSD 614 mn · 15.0% CAGR
- Transplant Biomarker Risk StratificationUSD 616 mn · 8.5% CAGR
- Neuromodulation Closed-Loop Brain-Computer InterfacesUSD 598 mn · 14.0% CAGR
- Clinic-Based Rehab Therapy RobotsUSD 632 mn · 9.5% CAGR
- Dystrophic Epidermolysis Bullosa ManagementUSD 632 mn · 8.0% CAGR
- Patient-Matched Orthopedic GuidesUSD 642 mn · 6.8% CAGR
- Handheld Point-of-Care UltrasoundUSD 660 mn · 9.5% CAGR